{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:54:05Z","timestamp":1720745645513},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.3816\/clm.2003.s.003","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T01:03:09Z","timestamp":1221181389000},"page":"S13-S17","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Epoetin Alfa Therapy for Patients with Hematologic Malignancies and Mild Anemia"],"prefix":"10.3816","volume":"4","author":[{"given":"David J.","family":"Straus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2003.s.003_bib1","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition","volume":"34","author":"Vogelzang","year":"1997","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2003.s.003_bib2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2003.s.003_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/bmj.322.7302.1560","article-title":"Fatigue in cancer","volume":"322","author":"Curt","year":"2001","journal-title":"BMJ"},{"key":"10.3816\/CLM.2003.s.003_bib4","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","article-title":"Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review","volume":"91","author":"Caro","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CLM.2003.s.003_bib5","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0277-5379(91)90020-E","article-title":"Changing clinical presentation of multiple myeloma","volume":"27","author":"Riccardi","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2003.s.003_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hon.663","article-title":"Erythropoietin for the treatment of anemia associated with hematological malignancy","volume":"19","author":"Littlewood","year":"2001","journal-title":"Hematol Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib7","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2003.s.003_bib8","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0959-8049(01)00169-1","article-title":"Predicting cancerassociated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey","volume":"37","author":"Coiffier","year":"2001","journal-title":"Eur J Cancer"},{"issue":"suppl","key":"10.3816\/CLM.2003.s.003_bib9","first-page":"234a","article-title":"Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): results from the European Cancer Anaemia Survey (ECAS)","volume":"100","author":"Ludwig","year":"2002","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2003.s.003_bib10","first-page":"18b","article-title":"Despite high prevalence of anemia and impact on high performance status (PS), anemia treatment (Tx) rate is low in multiple myeloma\/lymphoma (MM\/L) patients (pts) according to European Cancer Anaemia Survey (ECAS)","volume":"100","author":"Birgegard","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2003.s.003_bib11","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2002.07.177","article-title":"Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology","volume":"20","author":"Rizzo","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib12","series-title":"Cancer and treatment relatedanemia. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. V.1.2003","author":"Sabbatini","year":"2002"},{"key":"10.3816\/CLM.2003.s.003_bib13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group","volume":"15","author":"Glaspy","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib14","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group","volume":"16","author":"Demetri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib15","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of onceweekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11616","article-title":"Once-weekly dosing of epoetin-? increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy","author":"Shasha","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2003.s.003_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","article-title":"Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma","volume":"113","author":"Dammacco","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2003.s.003_bib18","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2002.08.131","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies","volume":"20","author":"Osterborg","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1046\/j.1365-2141.1998.01085.x","article-title":"A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes","volume":"103","author":"Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes","year":"1998","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2003.s.003_bib20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2003.s.003_bib21","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1001\/archinte.1995.00430190059008","article-title":"Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebocontrolled, double-blind trial","volume":"155","author":"Garton","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.3816\/CLM.2003.s.003_bib22","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2003.s.003_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","article-title":"The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy","volume":"28","author":"Dammacco","year":"1998","journal-title":"Int J Clin Lab Res"},{"issue":"suppl 1","key":"10.3816\/CLM.2003.s.003_bib24","first-page":"526a","article-title":"Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated wtih epoetin alfa (EPO)","volume":"84","author":"Rose","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2003.s.003_bib25","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non- Hodgkin's lymphoma: dose finding and identification of predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2003.s.003_bib26","first-page":"187","article-title":"High-doses epoetin alpha in patients with multiple myeloma-related anaemia: early response and effective maintenance treatment with a longer survival","volume":"6","author":"Niscola","year":"2003","journal-title":"Haema"},{"key":"10.3816\/CLM.2003.s.003_bib27","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"issue":"suppl","key":"10.3816\/CLM.2003.s.003_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0360-3016(02)03139-5","article-title":"Significant relationship between hemoglobin (Hb) level and quality of life (QOL) during chemoradiation: findings from an incremental analysis of a 442-patients prospective, community-based epoetin alfa study","volume":"54","author":"Shasha","year":"2002","journal-title":"Int J Radiat Oncol Biol Physics"},{"key":"10.3816\/CLM.2003.s.003_bib29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1200\/JCO.2003.02.136","article-title":"Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population","volume":"21","author":"Cella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0959-8049(02)00628-7","article-title":"Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa","volume":"39","author":"Patrick","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2003.s.003_bib31","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebocontrolled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2003.s.003_bib32","first-page":"287a","article-title":"Quality of life, blood transfusions, and toxicity, in anemic patients with advanced cancer receiving weekly erythropoietin while on chemotherapy: results from a phase III randomized double-blind placebo-controlled study","volume":"11","author":"Sloan","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2003.s.003_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/hon.722","article-title":"Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving nonplatinum chemotherapy","author":"Littlewood","year":"2003","journal-title":"Hematol Oncol"},{"key":"10.3816\/CLM.2003.s.003_bib34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"Br J Cancer"},{"issue":"suppl","key":"10.3816\/CLM.2003.s.003_bib35","first-page":"220a","article-title":"Epoetin alfa treatment improves quality of life and increasese hemoglobin levels during chemotherapy for lymphoma, chronic lymphocyctic leukemia (CLL), and multiple myeloma (MM) patients with mild-to-moderate anemia","volume":"100","author":"Straus","year":"2002","journal-title":"Blood"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511700446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511700446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:42:24Z","timestamp":1588920144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511700446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":35,"alternative-id":["S1526965511700446"],"URL":"https:\/\/doi.org\/10.3816\/clm.2003.s.003","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}